Tag Archives: HIV

In the News – BBC – Nussenzweig

HIV: new approach against virus “holds promise”   “Michel Nussenzweig of The Rockefeller University told BBC News: ‘This is different to treatment out there already on two counts. First because it comes from a human – so it is natural … More »

Tags: , ,

In first human study, new antibody therapy shows promise in suppressing HIV infection

In first human study, new antibody therapy shows promise in suppressing HIV infectionIn the first results to emerge from HIV patient trials of a new generation of so-called broadly neutralizing antibodies, Rockefeller University researchers have found the experimental therapy can dramatically reduce the amount of virus present in a patient’s blood. The work, reported this week in Nature, brings fresh optimism to the field of HIV immunotherapy and suggests new strategies for fighting or even preventing HIV infection. More »

Tags: , , , , ,

Research captures transient details of HIV genome packaging

Researchers have employed a recently developed technique to capture how a viral protein, Gag, selectively extracts and packages viral RNA into the viral particles that exported to new cells. More »

Tags: , , , , , ,

In the News – GlobeAndMail – Nussenzweig

HIV: Latent reservoir of virus in rare immune cells could help develop cure “Research at Rockefeller University suggests that a quiet body of immune cells that do not divide could harbour a reserve of HIV virus, a potential target for … More »

Tags: ,

Long-acting drug effectively prevents HIV-like infection in monkeys

Long-acting drug effectively prevents HIV-like infection in monkeysBecause cabotegravir would require only one injection every three months, researchers hope this new drug, which has begun clinical testing, could improve some patients’ ability to take HIV prevention medication properly. More »

Tags: , , , , , , , ,

Antibodies, together with viral ‘inducers,’ found to control HIV in mice

Antibodies, together with viral ‘inducers,’ found to control HIV in miceA new strategy devised by researchers at Rockefeller University harnesses the power of broadly neutralizing antibodies, along with a combination of compounds that induce viral transcription, in order to attack latent reservoirs of HIV-infected cells in an approach termed ‘shock and kill.’ More »

Tags: , , , , ,

Potent antibodies neutralize HIV and could offer new therapy, study finds

Rockefeller researchers in Michel Nussenzweig’s Laboratory of Molecular Immunology have found that a newly-discovered class of especially potent antibodies is effective at neutralizing HIV infection in mice for a 60 day period, longer than current antiretroviral drugs which require daily application. The antibodies, which suppressed the virus when used in combination, could one day be given to humans to treat the disease. More »

Tags: , , ,

Johannes Scheid wins 2012 Weintraub Graduate Student Award

Scheid is one of 13 awardees, all advanced graduate students at or near the completion of their studies in the biological sciences and chosen for the quality, originality and significance of their thesis research.
More »

Tags: ,

Research on killer HIV antibodies provides promising new ideas for vaccine design

By detailing the molecular workings of broadly neutralizing anti-HIV antibodies, found in so-called slow-progressing HIV patients, researchers hope to devise a way to arm those who are not equipped with exceptional immunological firepower. New clues reveal that some anti-HIV antibodies are especially sticky and target a previously unrecognized part of the virus. More »

Tags: , ,

Immune system uses a “leash” to restrict HIV’s spread

New research shows how an antiviral protein, tetherin, lashes newborn viral particles to infected cells, slowing the spread of infection. Understanding how this immune system defense works against HIV, Ebola and other deadly viruses could lead to better antiviral therapies. More »

Tags: , ,

A natural approach for HIV vaccine

Since HIV was first recognized in the early 1980s, scientists have tried and failed to develop a vaccine based on a handful of “super antibodies” that so far have been impossible to produce in humans. Now new research detailing the dynamic, natural immune response in “slow-progressing” HIV patients suggests that an effective HIV vaccine may come from a shotgun approach targeting several parts of the virus rather than a magic bullet targeting only one. More »

Tags: ,

Researchers unveil new monkey model for HIV

For the first time, scientists have succeeded in engineering a strain of HIV-1 that they can study in monkeys. Just one gene different from the deadly retrovirus that works all too well in humans, the new strain spreads in pig-tailed macaques almost as ferociously as it does in humans. Researchers at The Rockefeller University have already used it to demonstrate one method for preventing HIV-1 infection. With some minor changes, it could become a valuable model for vetting vaccine candidates. More »

Tags: ,

Scientists image a single HIV particle being born

For some, the saying “seeing is believing” has taken on a new meaning. In research to be published in the May 25 advance online issue of Nature, scientists at Rockefeller University and the Aaron Diamond AIDS Research Center have become the first to see, in real time and in plain sight, an HIV particle being born. The images, created using a technique that illuminates only the surface of the cell, where the virus assembles, have the potential to help researchers develop new treatments for AIDS. More »

Tags: , ,

Understanding primate evolution could aid HIV research

The discovery of an evolutionary duplication — the same genetic mutation in two species of monkey — is providing researchers with new insight into evolution and a potential new subject for an animal model for HIV. More »

Tags: ,

Experimental HIV vaccine gets a boost from ’70s-era discovery

A long-neglected molecule called poly-IC may see new life as a vaccine adjuvant. New research shows that, in combination with a novel AIDS vaccine, it helps mice maintain their immunity. More »

Tags: ,

Protein discovered that prevents HIV from spreading

In a study that could open up a new area of virology, scientists have found a molecule that keeps mutant strains of HIV from leaving their host cell. This new protein, tetherin, causes new virus particles to stay stuck to the outer membrane and be reabsorbed by the cell. More »

Tags: , ,

Analysis of Chinese AIDs epidemic shows surprising patterns

The Chinese province of Yunnan was the country’s point of entry for HIV, and is the area in which the AIDS epidemic is most widespread. The viral mutations that exist in Yunnan are far more diverse than anywhere else in the country, and recent research suggests that HIV in China may be spread by sexual contact more quickly than anyone believed. The result: a new subtype of the virus that has the potential to jumpstart a new epidemic. More »

Tags: ,

Dendritic cell receptor may be the key to an HIV vaccine

Recent attempts to develop a vaccine have elicited only limited action from two immune system cells, helper T cells and killer T cells. But Rockefeller University scientists working on a new approach have evidence that targeting a third group of immune cells, dendritic cells, may be even more effective than they’d previously believed. Now new research shows that the dendritic cells’ DEC-205 receptor may be the key to making it work. More »

Tags: , ,

Viral detectives: Researchers track down the location of HIV-1 assembly in human cells

New research by Rockefeller University and ADARC scientists pinpoints the location of HIV-1 assembly in human immune cells. Although the assembly site had long been a topic of dispute, the researchers show conclusively that the virus is being built in the cells’ plasma membranes and not, as many had supposed, in internal cellular compartments called endosomes. More »

Tags: , , ,

HIV-1 kills immune cells in the gut that may never bounce back

People with HIV have been living longer, healthier lives since the development of highly active antiretroviral therapy (or HAART) in 1995. In fact, most patients on the drug regimen do so well that, according to blood tests, their immune cells appear to return to pre-HIV levels. But two new studies from Rockefeller University and the Aaron Diamond AIDS Research Center show that within the gastrointestinal tract, recovery of immune cells is incomplete despite years of prolonged treatment, suggesting the need for additional ways to monitor immune system health, and the need for hypervigilance as HIV-positive patients live into their forties, fifties, sixties and beyond. More »

Tags: ,